Axsome Therapeutics, Inc. Forecast, price target & analysts
Axsome Therapeutics, Inc. Target price 2026 - Analyst rating & recommendation
Axsome Therapeutics, Inc. Classifications & Recommendation
Axsome Therapeutics, Inc. Price Target
| Target Price | $281.52 |
| Price | $195.09 |
| Potential |
44.30%
register free of charge
|
| Number of Estimates | 23 |
|
23 Analysts have issued a price target Axsome Therapeutics, Inc. 2027 .
The average Axsome Therapeutics, Inc. target price is $281.52.
This is
44.30%
register free of charge
$399.00
104.52%
register free of charge
$202.00
3.54%
register free of charge
|
|
| A rating was issued by 28 analysts: 26 Analysts recommend Axsome Therapeutics, Inc. to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Axsome Therapeutics, Inc. stock has an average upside potential 2027 of
44.30%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 638.50 | 982.30 |
| 65.55% | 53.84% | |
| EBITDA Margin | -25.48% | -10.41% |
| 64.16% | 59.14% | |
| Net Margin | -28.69% | -12.87% |
| 61.48% | 55.14% |
24 Analysts have issued a sales forecast Axsome Therapeutics, Inc. 2026 . The average Axsome Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
8 Analysts have issued an Axsome Therapeutics, Inc. EBITDA forecast 2026. The average Axsome Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
24 Axsome Therapeutics, Inc. Analysts have issued a net profit forecast 2026. The average Axsome Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -3.68 | -2.42 |
| 38.56% | 34.24% | |
| P/E | negative | |
| EV/Sales | 10.33 |
24 Analysts have issued a Axsome Therapeutics, Inc. forecast for earnings per share. The average Axsome Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Axsome Therapeutics, Inc....
Current Axsome Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Piper Sandler |
Locked
➜
Locked
|
Locked | Sep 18 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 31 2026 |
| Mizuho |
Locked
➜
Locked
|
Locked | Aug 12 2026 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Aug 11 2026 |
| Needham |
Locked
➜
Locked
|
Locked | Aug 11 2026 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Aug 11 2026 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Aug 11 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Sep 18 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 31 2026 |
|
Locked
Mizuho:
Locked
➜
Locked
|
Aug 12 2026 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Aug 11 2026 |
|
Locked
Needham:
Locked
➜
Locked
|
Aug 11 2026 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Aug 11 2026 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Aug 11 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
